Sutro Biopharma, Inc. (STRO) – What Are Brokerages Saying About This Stock?

Shares of Sutro Biopharma, Inc. (NASDAQ:STRO) have received a consensus rating of “Buy” from the thirteen research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $49.50.

A number of research firms have commented on STRO. Stifel Nicolaus set a $48.00 price target on Sutro Biopharma and gave the stock a “buy” rating in a research note on Friday, August 7th. Citizens Jmp dropped their price objective on Sutro Biopharma from $41.00 to $34.00 and set a “market outperform” rating for the company in a research note on Thursday, August 13th. Wall Street Zen raised Sutro Biopharma from a “strong sell” rating to a “sell” rating in a research note on Saturday. Wells Fargo & Company started coverage on Sutro Biopharma in a report on Wednesday, September 30th. They issued an “overweight” rating and a $49.00 price objective on the stock. Finally, HC Wainwright reissued a “buy” rating on shares of Sutro Biopharma in a research note on Friday, October 16th.

Hedge Funds Weigh In On Sutro Biopharma

Several hedge funds and other institutional investors have recently added to or reduced their stakes in STRO. Squarepoint Ops LLC acquired a new position in Sutro Biopharma during the second quarter worth about $1,844,000. Seven Fleet Capital Management LP acquired a new stake in shares of Sutro Biopharma in the second quarter valued at approximately $5,283,000. Wellington Management Group LLP acquired a new stake in shares of Sutro Biopharma in the second quarter valued at approximately $359,000. Merck & Co. Inc. purchased a new position in shares of Sutro Biopharma during the 2nd quarter worth approximately $9,042,053. Finally, Bank of New York Mellon Corp purchased a new position in shares of Sutro Biopharma during the 2nd quarter worth approximately $1,373,000. Hedge funds and other institutional investors own 96.99% of the company’s stock.

Sutro Biopharma Price Performance

STRO opened at $9.11 on Thursday. The firm has a market capitalization of $151.04 million, a price-to-earnings ratio of -0.76 and a beta of 1.49. The company’s 50 day simple moving average is $15.15 and its two-hundred day simple moving average is $22.77. Sutro Biopharma has a 1-year low of $7.15 and a 1-year high of $43.85.

Sutro Biopharma (NASDAQ:STRO) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($2.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.19) by ($0.14). The business had revenue of $9.84 million during the quarter, compared to the consensus estimate of $11.96 million. On average, equities analysts anticipate that Sutro Biopharma will post -8.41 earnings per share for the current fiscal year.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc is a clinical-stage biotechnology company focused on developing medicines for cancer and other serious diseases. The company uses its proprietary XpressCF cell-free protein synthesis platform to design and manufacture targeted biologic therapies, including antibody-drug conjugates (ADCs) and cancer immunotherapies.

Sutro’s research programs have included luveltamab tazevibulin, also known as STRO-002, a folate receptor alpha-targeted ADC being investigated for ovarian and endometrial cancers.